Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Thomas Bachelot(Centre Léon Bérard), A Wroński(Institute of Neurobiology), Étienne Brain(Institut Curie), Joanna Streb, Fabio Puglisi(University of Udine), Fernando Palacios Salas, David Miles(Guy's Hospital), Hamdy Abdel Azeem, Igor Bondarenko(Dnipro State Medical University), Zeba Aziz(Rashid Latif Medical College), Rabab Gaafar, Bruno Coudert(Ludwig Boltzmann Institute for Cancer Research), Filippo Montemurro(Roche (Switzerland)), Sophie Barrett, Ana Ferreira, Dimitris Mavroudis, Carlo Tondini(Ospedale Papa Giovanni XXIII), Johannes Ettl(TUM Klinikum), Juan Antonio Matus, Francesco Ricci(Istituto Dermopatico dell'Immacolata), Michael P. Lux(Brüderkrankenhaus St. Josef Paderborn), Florence Dalenc(Institut Claudius Regaud), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Haralabos P. Kalofonos(University of Patras), Andrew Wardley(UK Research and Innovation), Christophe Perrin(Centre Eugène Marquis), Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Yolande Du Toit(Roche (Switzerland)), Mario Campone(Institut de Cancérologie de l'Ouest), Max S. Mano, Eva Ciruelos(Hospital Universitario 12 De Octubre), Nicolas Lindegger(Takeda (Japan)), Anna Cariello(Azienda Unità Sanitaria Locale Della Romagna), Taher Altwegeiri, Jean-Louis Merot, Andreas Schneeweiß(German Cancer Research Center), Huiping Li(Peking University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Oliver Hoffmann(University of Duisburg-Essen), Xichun Hu(Fudan University Shanghai Cancer Center), Niklas Loman(Lund University), Sunil Verma, Carlos Beato, Tamar Peretz‐Yablonski(Hadassah Medical Center), Kamel Bouzid, István Láng(Roche (Switzerland)), Shani Paluch–Shimon(Hebrew University of Jerusalem), V. Easton(Roche (Switzerland)), Hassan Errihani
Cited by 117
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k